Sperogenix Therapeutics
Latest round
- Series B
Last raised
- Oct 2023
Total raised
- Undisclosed
Investors
- 3
About Sperogenix Therapeutics
Established in 2015 and based in Beijing, China, Sperogenix Therapeutics is a company focusing on the research, development and commercialization of new drugs for rare diseases in China, providing commercial development, clinical development and other businesses. Mr. Yan Zhiyu, the founder and CEO of the company, has been in the pharmaceutical industry for 28 years, and has held positions such as General Manager of Acetelon China and clinical work in the Department of Cardiology of Shanghai Zhongshan Hospital. The company develops rare disease drugs through commercial development and clinical development. Specifically, this includes introducing drug products for approval in China, collaborating with pharmaceutical companies to develop clinical drugs, and designing and implementing clinical trials that are applicable to China's regulatory requirements to launch the drugs. Specific products are available for the treatment of pulmonary hypertension, myasthenia gravis and other neurological and genetic metabolic diseases.
Who invested in Sperogenix Therapeutics
3 investors across 2 rounds
See all investors in Sperogenix Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sperogenix Therapeutics
Who invested in Sperogenix Therapeutics?
Sperogenix Therapeutics has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sperogenix Therapeutics raised?
Sperogenix Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Sperogenix Therapeutics last raise money?
Sperogenix Therapeutics's most recent round on record is a Series B, in Oct 2023.
What does Sperogenix Therapeutics do?
Established in 2015 and based in Beijing, China, Sperogenix Therapeutics is a company focusing on the research, development and commercialization of new drugs for rare diseases in China, providing commercial development, clinical development and other businesses.
Where is Sperogenix Therapeutics headquartered?
Sperogenix Therapeutics is headquartered in Beijing, China.
Which VCs invest in companies like Sperogenix Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Sperogenix Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Sperogenix Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.